Agios Pharmaceuticals


Roth Capital Weighs in on Biotech: Sarepta Therapeutics Inc (SRPT), Bluebird Bio Inc (BLUE), Agios Pharmaceuticals Inc (AGIO)

On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT), Bluebird Bio Inc (NASDAQ:BLUE), and Agios …

Roth Capital Weighs in on Biotech: Sarepta Therapeutics Inc (SRPT), Bluebird Bio Inc (BLUE), Agios Pharmaceuticals Inc (AGIO)

On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT),Bluebird Bio Inc (NASDAQ:BLUE), and Agios Pharmaceuticals …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces First Patient Dosed with AG-881 in Study in Patients with Advanced Solid Tumors

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced dose administration for the first …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces New Data from Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Hematologic Malignancies

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced new data from the dose-escalation …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces FDA Orphan Drug Designation Granted to AG-120

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced that the U.S.

Company Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc to Present Clinical and Preclinical Data at the 20th Congress of the European Hematology Association

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced that new clinical and preclinical …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Myelogenous Leukemia with an IDH1 Mutation

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced that the U.S.

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, reported financial results and business …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced that it plans to …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency

Agios Pharmaceuticals Inc (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the United States Food …